Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Neumora Therapeutics, Inc. (NMRA) had Return on Tangible Equity of -84.92% for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-243.79M |
|
-- |
|
-- |
|
$263.46M |
|
$-263.46M |
|
$19.86M |
|
$-243.61M |
|
$-243.61M |
|
$-243.79M |
|
$-243.79M |
|
$-243.79M |
|
$-243.79M |
|
$-263.46M |
|
$-268.55M |
|
159.38M |
|
159.38M |
|
$-1.53 |
|
$-1.53 |
|
| Balance Sheet Financials | |
$314.06M |
|
$1.14M |
|
$2.92M |
|
$316.97M |
|
$29.89M |
|
-- |
|
$0.02M |
|
$29.91M |
|
$287.06M |
|
$287.06M |
|
$287.06M |
|
161.71M |
|
| Cash Flow Statement Financials | |
$-182.94M |
|
$-70.56M |
|
$21.60M |
|
$375.25M |
|
$143.36M |
|
$-231.89M |
|
$39.99M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
10.51 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-182.94M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-84.92% |
|
|
Return on Tangible Equity |
-84.92% |
-76.91% |
|
-84.92% |
|
$1.78 |
|
$-1.15 |
|
$-1.15 |
|